New England Journal of Medicine2019Open AccessHighly Cited

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Mansoor Husain, Andreas L. Birkenfeld, Morten Donsmark et al.

1,846 citations2019Open Access — see publisher for license terms1 related compound

Research Article — Peer-Reviewed Source

Original research published by Husain et al. in New England Journal of Medicine. Redistributed under Open Access — see publisher for license terms. MedTech Research Group provides these references for informational purposes. We do not conduct original research. All studies are the work of their respective authors and institutions.

Abstract

Establishing cardiovascular safety of new therapies for type 2 diabetes is important. Safety data are available for the subcutaneous form of the glucagon-like peptide-1 receptor agonist semaglutide but are needed for oral semaglutide.

Full Text

Full text is available at the publisher.

Read at Publisher
Article Details
DOI10.1056/nejmoa1901118
JournalNew England Journal of Medicine
Year2019
AuthorsMansoor Husain, Andreas L. Birkenfeld, Morten Donsmark, Kathleen Dungan, Freddy G. Eliaschewitz, Denise Reis Franco, Ole Kleist Jeppesen, Ildiko Lingvay, Ofri Mosenzon, Sue D. Pedersen, Cees J. Tack, Mette S. Thomsen, Tina Vilsbøll, Mark Warren, Stephen C. Bain
LicenseOpen Access — see publisher for license terms
Citations1,846